Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Financial support options for Paxlovid are changing, but remain in place this winter for Medicare recipients and for others ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...

About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million.

据外媒新闻，美国FDA要求辉瑞和葛兰素史克（GSK）生产的呼吸道合胞病毒（RSV）疫苗须在标签上增加有关罹患吉兰-巴雷综合征（GBS）风险的警告。吉兰-巴雷综合征是一种罕见的神经系统疾病，其病因可能与感染和免疫反应有关，特征性症状为对称性的肢体无力、 ...

Recently, an 80-year-old man in Ahmedabad tested positive for human metapneumovirus (hMPV), adding to the growing cases of ...